Biopharmaceutical and biotech startups companies face many challenges in the quest to advance early-stage drug candidates through development, clinical trials, and onto commercialization.
Funding is among the top priorities and is essential for the continued progress of promising drug candidates. Estimates vary, but it can cost $8-10 million just to get to IND stage, another $8-10 million for Phase I, and $20-40 million for Phase II, depending on design. Phase III costs considerably more.
Startup programs, grants, and funding sources can help accelerate the journey to your next milestone.
Our strategic venture capital arm globally invests in innovative ideas, driving transformation. Discover the future of healthcare and technology with us.
Join forces with our open innovation programs, stimulating creative solutions for humanity’s greatest challenges. Explore, innovate, and shape the future with us.
Explore the Bill & Melinda Gates Foundation’s grant opportunities. A valuable collaborator resource to solving key health and development problems worldwide.
Uncover key insights from our Life Science Executive Summit, a platform for biotech innovation, funding strategies, and process development.
Unlock the potential of biotech with important excerpts from our Emerging Biotech Executive Summit. Gain insights from industry leaders and advance your molecule to market.
We offer several grant programs to help biopharmaceutical and biotech start-ups, entrepreneurs, scientists, and students bring innovative ideas to the next level.
The Advance Biotech Grant Program is offered on a regular basis in different regions of the world. The program recognizes stand-out emerging biopharmaceutical and biotech start-ups and awards grant recipients with products, services, and consultation to advance production and help accelerate the path to commercialization. Since 2014, more than 40 biotech startups have been recognized through this Program. We are honored to support their missions as they pursue therapeutic solutions for patients suffering from cancer, brain tumors, osteoarthritis, and cardiovascular disorders. To be considered for the grant, you must describe your therapeutic focus, clinical strategy, and explain how we can help you overcome challenges and address gaps in expertise to bring your innovation across the finish line.
Our Research Challenge is a competition for technology pioneers at the leading edge of innovation. In this challenge, you’ll be presented with a task and a time limit, and the opportunity to apply your expertise and competitive spirit. Our research grants are designed to stimulate innovative research in challenging areas of future importance.
Lack of funding is a reason why promising therapeutics being developed at emerging, start-up biotechs and biopharmaceutical companies may fail to reach commercial status. With the cost to develop a drug estimated to be millions, funding is a challenge for all early-stage drug developers. There are many financing options, from biotech crowdfunding, nondilutive funding, and noncoercive funding, to biotech grants, angel investors, venture capital and other resources. Here are some good places to start in your search for funding.
Venture capital (VC) investors look for disruptive technologies that align with their focus areas and a team that can deliver on that vision. When an early-stage, emerging biotech or biopharmaceutical company can clearly define why they are innovative and how they differentiate from others in addressing a relevant issue, the VC will take notice. Leadership that shows both focus and agility increase the likelihood of a successful partnership. Likewise, the entrepreneur should look for VCs that take an active role in translating innovations towards commercial success.
M Ventures, Amsterdam, The Netherlands, a subsidiary of Merck is a venture fund that joins forces with industry visionaries to maintain science and technology leadership for the next generation
For very early-stage biotech and biopharmaceutical companies, especially those whose founders are new to corporate leadership, an incubator or accelerator facility may be the right solution. These facilities provide not only reasonably priced lab-space and access to a core facility, but a network of support from legal and financial management resources to funding and coaching. These resources can go a long way to help establish a new biotech or biopharmaceutical entity.
Identifying the considerations, resources, and support you need to develop a new biologics candidate
Establishing safety and effectiveness for your Investigational New Drug (IND) application
Accelerating your process development with tips, templates, and application guides
Progressing from scale-up and tech transfer to quality production for trials and commercialization
Navigating one of the world’s most regulated industries starts with a trusted guide
To continue reading please sign in or create an account.
Don't Have An Account?